About the newsletter
PSOGI World News is the official scientific publication of the Peritoneal Surface Oncology Group International, the leading international society in peritoneal disease. Each issue gathers expert opinion pieces and reviews on cytoreductive surgery, HIPEC, PIPAC and emerging intraperitoneal therapies.
Main topics of the April issue
Colorectal cancer with peritoneal metastases
Several articles discuss the results of the PRODIGE 7 trial, which did not show a clear benefit of HIPEC with oxaliplatin. However, authors argue that other combinations — especially with mitomycin C — still make sense in selected patient groups with colorectal peritoneal carcinomatosis. The takeaway is not "HIPEC does not work", but rather "we need to refine which drug we use".
Peritoneal pseudomyxoma
The issue analyses the role of HIPEC both in initial surgery and in reoperations of peritoneal pseudomyxoma. The conclusion is that HIPEC appears more justified in the initial surgery than in re-intervention, where its contribution is less evident.
Mucinous appendiceal tumors
Emerging therapies are featured, including palbociclib, intraperitoneal paclitaxel and BromAc, with promising signals. Evidence is still limited, but these are interesting avenues for difficult-to-treat tumors.
Neoadjuvant chemotherapy
Several authors insist that pre-operative chemotherapy is not always beneficial and that the decision must be individualized, taking into account the tumor type, the extent of disease and the patient's condition. An individualized prognostic assessment is key.
Organoids and precision medicine
The newsletter raises the idea that tumor-derived organoids (mini tumor replicas grown in the lab) could help predict which treatment will work best for each patient. A promising avenue for truly personalised intraperitoneal chemotherapy.
Advanced ovarian and tubo-ovarian cancer
Current evidence and ongoing clinical trials on HIPEC after surgery in advanced ovarian cancer are reviewed — an area where HIPEC has increasingly solid data in selected patients.
"HIPEC still has a role, but we must refine when, how and with which drugs to use it."
— Central idea of the April 2026 issue
Why it matters to us
At Quenet Torrent Institute we follow the PSOGI scientific debates closely because they directly shape our daily clinical practice. We tailor the indication of HIPEC to tumor type, patient status and expected surgical outcome, and we review every case in a multidisciplinary setting. Proper patient selection together with a complete cytoreductive surgery are, today, the two factors that most influence prognosis.
For deeper clinical context, see our articles on prognosis and life expectancy in peritoneal carcinomatosis, survival by primary tumor and the Peritoneal Cancer Index (PCI).
Original source: full newsletter on the PSOGI website.
Read on PSOGI World News